Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas

Cancer

Volumn 119, Issue 4, 2013, Pages 806-813

  Wang, Xiao Wei ^a,b,c   Boisselier, Blandine ^a,b,c   Rossetto, Marta ^a,b,c   Marie, Yannick ^d   Idbaih, Ahmed ^a,b,c   Mokhtari, Karima ^a,b,c   Gousias, Konstantinos ^e   Hoang Xuan, Khê ^a,b,c   Delattre, Jean Yves ^a,b,c   Simon, Matthias ^e   Labussière, Marianne ^a,b,c   Sanson, Marc ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CNRS   (France)

^d ICM   (France)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

glioblastoma; glioma; IDH1; prognostic markers; single nucleotide polymorphism

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CODON; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; CODON; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873413047     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27798     Document Type: Article

References (15)

1. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H,. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009; 15: 6002-6007.
2. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150-4154.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
4. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-744.
5. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009; 11: 341-347.
6. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-1066.
7. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28: 2348-2355.
8. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011; 224: 334-343.
9. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17: 72-79.
10. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single-nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010; 28: 2356-2364.
11. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer. 2008; 122: 1778-1786.
12. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2001; 57: 1278-1281.
13. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006; 60: 740-743.
14. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
15. Ho PA, Kopecky KJ, Alonzo TA, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011; 118: 4561-4566.